Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

4,121 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cost effectiveness of external hip protectors in the hospital setting: a modeling study.
Stollenwerk B, Waldeyer R, Klein-Meding C, Müller D, Stock S. Stollenwerk B, et al. Among authors: muller d. Nurs Econ. 2014 Mar-Apr;32(2):89-98. Nurs Econ. 2014. PMID: 24834633
A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
Zindel S, Stock S, Müller D, Stollenwerk B. Zindel S, et al. Among authors: muller d. BMC Health Serv Res. 2012 Jul 9;12:192. doi: 10.1186/1472-6963-12-192. BMC Health Serv Res. 2012. PMID: 22776616 Free PMC article.
Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes.
Müller D, Borsi L, Stracke C, Stock S, Stollenwerk B. Müller D, et al. Eur J Health Econ. 2015 Jun;16(5):517-27. doi: 10.1007/s10198-014-0605-5. Epub 2014 May 13. Eur J Health Econ. 2015. PMID: 24818587
Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
Simoes Correa-Galendi J, Del Pilar Estevez Diz M, Stock S, Müller D. Simoes Correa-Galendi J, et al. Among authors: muller d. Appl Health Econ Health Policy. 2020 Jun 15. doi: 10.1007/s40258-020-00599-0. Online ahead of print. Appl Health Econ Health Policy. 2020. PMID: 32537695
Predictive modeling to identify potential participants of a disease management program hypertension.
Lenti P, Kottmair S, Stock S, Shukri A, Müller D. Lenti P, et al. Among authors: muller d. Expert Rev Pharmacoecon Outcomes Res. 2020 Jun 30:1-8. doi: 10.1080/14737167.2020.1780919. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2020. PMID: 32600073
Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review.
Müller D, Pulm J, Gandjour A. Müller D, et al. Value Health. 2012 Mar-Apr;15(2):284-98. doi: 10.1016/j.jval.2011.11.030. Epub 2012 Feb 2. Value Health. 2012. PMID: 22433760 Review.
O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
Heinzel A, Müller D, Yekta-Michael SS, Ceccon G, Langen KJ, Mottaghy FM, Wiesmann M, Kocher M, Hattingen E, Galldiks N. Heinzel A, et al. Among authors: muller d. Neuro Oncol. 2017 Sep 1;19(9):1271-1278. doi: 10.1093/neuonc/now310. Neuro Oncol. 2017. PMID: 28204572 Free PMC article.
Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach.
Gandjour A, Müller D. Gandjour A, et al. Among authors: muller d. Appl Health Econ Health Policy. 2014 Oct;12(5):471-6. doi: 10.1007/s40258-014-0112-y. Appl Health Econ Health Policy. 2014. PMID: 25027546
Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
Mensch A, Stock S, Stollenwerk B, Müller D. Mensch A, et al. Among authors: muller d. Pharmacoeconomics. 2015 Mar;33(3):271-83. doi: 10.1007/s40273-014-0236-9. Pharmacoeconomics. 2015. PMID: 25404426
Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.
Heinzel A, Stock S, Langen KJ, Müller D. Heinzel A, et al. Among authors: muller d. Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1089-96. doi: 10.1007/s00259-012-2093-0. Epub 2012 Mar 15. Eur J Nucl Med Mol Imaging. 2012. PMID: 22419257
4,121 results
Jump to page